Vicebio Secures Major Funding to Develop Vaccines for Respiratory Diseases

Monday, 23 September 2024, 00:00

Funding for respiratory disease vaccines has grown significantly, highlighted by Vicebio's recent $100 million investment. Vicebio, utilizing molecular clamp technology, aims to create multivalent vaccines targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The company's efforts focus on addressing unmet medical needs in vulnerable populations, especially the elderly and immunocompromised. The increased focus on respiratory pathogens has accelerared vaccine development initiatives.
Labiotech
Vicebio Secures Major Funding to Develop Vaccines for Respiratory Diseases

Funding for Respiratory Disease Vaccines

Vicebio, a UK-based vaccine company, recently completed a $100 million series B funding round led by TCGX, with contributions from Goldman Sachs Alternatives, Avoro Ventures, venBio, and others. This significant funding aims to advance Vicebio's innovative multivalent vaccine candidates.

Molecular Clamp Technology Explained

Molecular clamp technology enhances the efficacy of vaccines by stabilizing viral surface proteins in their prefusion state. This approach is critical for generating robust immune responses. Emmanuel Hanon, CEO of Vicebio, noted that the technology enables strong protective responses against pathogens by keeping the viral glycoproteins in the most immunogenic conformation.

Market Trends and Future Directions

  • The respiratory vaccine market is projected to reach nearly $70 billion by 2024.
  • Investment in respiratory virus vaccine development has seen a notable increase.
  • There is a rising need for vaccines that can protect against multiple respiratory pathogens, particularly for high-risk groups.

For more information about the potential of Vicebio's vaccine technology and its impact on public health, consider visiting additional resources.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe